Erratum: Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice (Acta Pharmacologica Sinica (2013) 35:1 (124-34) DOI:10.1038/aps.2013.152);Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice

Acta Pharmacologica Sinica

Volumn 35, Issue 1, 2014, Pages 124-134

  Yan, Wei ^a,b   Wang, Ting Yu ^a   Fan, Qi Ming ^a   Du, Lin ^a   Xu, Jia Ke ^c   Zhai, Zan Jing ^a   Li, Hao Wei ^a   Tang, Ting Ting ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Wendeng Zhenggu Hospital of Shandong Province   (China)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

apoptosis; bone microenvironment; breast cancer; in vivo imaging; lytic lesion; naphthoquinone; osteoclast; plumbagin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; CHOLECYSTOKININ OCTAPEPTIDE; LIPOCORTIN 5; PLUMBAGIN; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; BONE EROSION; BONE TISSUE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INOCULATION; MICRO-COMPUTED TOMOGRAPHY; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; TIBIA; TUMOR GROWTH; X RAY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHOQUINONES; OSTEOCLASTS; TUMOR MICROENVIRONMENT;

EID: 84891818898     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.2     Document Type: Erratum

References (35)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50. (Pubitemid 46655601)
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-93. (Pubitemid 37328925)
3. Rose A, Siegel PM. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 2006; 93: 931-43. (Pubitemid 44520875)
4. Guise TA, Yin JJ, Taylor S, Kumagai Y, Dallas M, Boyce B, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544.
5. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88: 1082-90. (Pubitemid 30127670)
6. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-7. (Pubitemid 46211499)
7. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-71. (Pubitemid 44023154)
8. Durie BGM, Katz M, Crowley J, Woo SB, Hande K, Richardson PG, et al. Osteonecrosis of the jaw and bisphosphonates. New Engl J Med 2005; 353: 99-102.
9. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Mineral Res 2008; 23: 826-36. (Pubitemid 351768801)
10. Choi S, Lim MH, Kim KM, Jeon BH, Song WO, Kim TW. Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor. Toxicol Appl Pharmacol 2011; 257: 165-73.
11. Zhang Y, Zhu G, Gu S, Chen X, Hu H, Weng S. Genistein inhibits osteolytic bone metastasis and enhances bone mineral in nude mice. Environ Toxicol Pharmacol 2010; 30: 37-44.
12. Li Y, Bäckesjö CM, Haldosén LA, Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol 2009; 609: 13-8.
13. Park H, Bergeron E, Senta H, Guillemette K, Beauvais S, Blouin R, et al. Sanguinarine induces apoptosis of human osteosarcoma cells through the extrinsic and intrinsic pathways. Biochem Biophys Res Commun 2010; 399: 446-51.
14. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-?B activation and NF-?B-regulated gene products through modulation of p65 and I?B? kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006; 281: 17023-33.
15. Paiva SR, Figueiredo MR, Aragão TV, Kaplan MAC. Antimicrobial activity in vitro of plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz 2003; 98: 959-61. (Pubitemid 38019547)
16. Sharma I, Gusain D, Dixit VP. Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits. Indian J Physiol Pharmacol 1991; 35: 10-4.
17. Checker R, Sharma D, Sandur SK, Khanam S, Poduval T. Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol 2009; 9: 949-58.
18. Manu KA, Shanmugam MK, Rajendran P, Li F, Ramachandran L, Hay HSIN, et al. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer 2011; 10: 107.
19. Kuo PL, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006; 5: 3209-21.
20. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008; 68: 9024-32.
21. Sand JM, Hafeez BB, Jamal MS, Witkowsky O, Siebers EM, Fischer J, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis 2012; 33: 184-90.
22. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8. (Pubitemid 40052322)
23. Sung B, Oyajobi B, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther 2012; 11: 350-9.
24. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486-95. (Pubitemid 32675200)
25. Price JT, Quinn JMW, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65: 4929-38. (Pubitemid 40740833)
26. Park HH, Lee KY, Kim SH, Lee YJ, Koh SH. L-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway. Toxicology 2009; 265: 80-6.
27. Zheng Y, Zhou H, Modzelewski JRK, Kalak R, Blair JM, Seibel MJ, et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007; 67: 9542-48. (Pubitemid 47535945)
28. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski J, Seibel MJ, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471.
29. Jiang Y, Huang Y, Cheng C, Lu W, Zhang Y, Liu X, et al. Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPAR? up-expression in MDA-MB-231 cells. Exp Mol Pathol 2011; 91: 768-74.
30. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-?B and Bcl-2. J Cell Biochem 2008; 105: 1461-71.
31. Kawiak A, Zawacka-Pankau J, Lojkowska E. Plumbagin induces apoptosis in Her2-overexpressing breast cancer cells through the mitochondrial-mediated pathway. J Nat Prod 2012; 75: 747-51.
32. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008; 68: 9024-32.
33. Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O, Verma AK. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKC{varepsilon}, Stat3 and neuroendocrine markers. Carcinogenesis 2012; 33: 2586-92.
34. Devi PU, Solomon F, Sharada A. Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties. Pharm Biol 1999; 37: 231-6. (Pubitemid 29500421)
35. Li Z, Xiao J, Wu X, Li W, Yang Z, Xie J, et al. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Curr Mol Med 2012; 12: 967-81.